Vina Leite - Goodrx Holdings Chief Officer
| GDRX Stock | USD 4.75 0.04 0.84% |
Insider
Vina Leite is Chief Officer of Goodrx Holdings
| Age | 55 |
| Address | 2701 Olympic Boulevard, Santa Monica, CA, United States, 90404 |
| Phone | 855 268 2822 |
| Web | https://www.goodrx.com |
Goodrx Holdings Management Efficiency
The company has return on total asset (ROA) of 0.0362 % which means that it generated a profit of $0.0362 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.022 %, meaning that it created $0.022 on every $100 dollars invested by stockholders. Goodrx Holdings' management efficiency ratios could be used to measure how well Goodrx Holdings manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Goodrx Holdings' Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to rise to 0.02 in 2025, whereas Return On Tangible Assets are likely to drop 0.02 in 2025. At this time, Goodrx Holdings' Net Tangible Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 155.7 M in 2025, whereas Total Assets are likely to drop slightly above 1.3 B in 2025.Similar Executives
| Showing other executives | INSIDER Age | ||
| Bud JD | Simulations Plus | N/A | |
| Serge Saxonov | 10X Genomics | 48 | |
| Jim Wilbur | 10X Genomics | N/A | |
| Jona Raasch | National Research Corp | 65 | |
| Nate Gross | Doximity | N/A | |
| Bradford Gay | American Well Corp | 47 | |
| Perry Gold | Doximity | N/A | |
| M Duffy | Evolent Health | 61 | |
| Catherine Jacobson | Teladoc | 56 | |
| Michael Hilton | Accolade | 59 | |
| Richard Napolitano | Teladoc | 57 | |
| Jessica Somers | Evolent Health | N/A | |
| Aammaad Shams | Evolent Health | 40 | |
| Helen Hrdy | National Research Corp | 60 | |
| Rajeev Singh | Accolade | 57 | |
| Jim Rivas | Doximity | N/A | |
| Jason Alger | Health Catalyst | 41 | |
| Nicolette Sherman | Certara | 54 | |
| Stephen Schlegel | American Well Corp | 57 | |
| Carolina Lobo | Accolade | N/A | |
| Justin McAnear | 10X Genomics | 48 | |
Management Performance
| Return On Equity | 0.022 | ||||
| Return On Asset | 0.0362 |
Goodrx Holdings Leadership Team
Elected by the shareholders, the Goodrx Holdings' board of directors comprises two types of representatives: Goodrx Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Goodrx. The board's role is to monitor Goodrx Holdings' management team and ensure that shareholders' interests are well served. Goodrx Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Goodrx Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bansi Nagji, President Healthcare | ||
| Mike Walsh, President Marketplace | ||
| Douglas Hirsch, Cofounder Director | ||
| Andrew Slutsky, Chief Officer | ||
| Nitin Shingate, Chief Officer | ||
| Mark Hull, Chief Officer | ||
| Babak Azad, Chief Communications | ||
| Whitney Notaro, Vice Relations | ||
| Scott Wagner, Principal Officer | ||
| Trevor Bezdek, Cofounder Chairman | ||
| Wendy Barnes, Chief Officer | ||
| Vina Leite, Chief Officer | ||
| Karsten Voermann, Chief Officer | ||
| Aubrey Reynolds, Director Relations | ||
| Gracye Cheng, General Secretary | ||
| Ryan Sullivan, Chief Officer | ||
| Romin Nabiey, Interim Officer | ||
| Justin Fengler, Senior Operations | ||
| Raj Beri, Chief Officer | ||
| Christopher McGinnis, Chief Officer |
Goodrx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Goodrx Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.022 | ||||
| Return On Asset | 0.0362 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.19 % | ||||
| Current Valuation | 1.93 B | ||||
| Shares Outstanding | 106.74 M | ||||
| Shares Owned By Insiders | 11.60 % | ||||
| Shares Owned By Institutions | 63.46 % | ||||
| Number Of Shares Shorted | 6.81 M | ||||
| Price To Book | 2.54 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Goodrx Stock Analysis
When running Goodrx Holdings' price analysis, check to measure Goodrx Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Goodrx Holdings is operating at the current time. Most of Goodrx Holdings' value examination focuses on studying past and present price action to predict the probability of Goodrx Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Goodrx Holdings' price. Additionally, you may evaluate how the addition of Goodrx Holdings to your portfolios can decrease your overall portfolio volatility.